Agoracom Blog Home

Posts Tagged ‘Field Trip Health Ltd.’

Novamind $NM.ca $NVMDF Doubles in Size, Adds Four New Psychedelic Mental Health Clinics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:38 AM on Tuesday, May 4th, 2021
  • Announced that it will open four new Cedar Psychiatry clinics doubling its network to eight total locations
  • Begun construction on three of the New Clinics and leased a fourth additional property
  • Expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021

New clinics represent the first phase of Novamind’s national expansion strategy

TORONTO, ON / May 4, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the “New Clinics”), doubling its network to eight total locations.

The expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 225% increase.

Novamind has begun construction on three of the New Clinics and leased a fourth additional property. Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind’s national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021.

Novamind’s investment in the expansion of its clinic network follows a significant increase in demand from clients for mental health services to address existing unmet needs and the effects of the Covid-19 pandemic. All Cedar Psychiatry clinics currently have a 2-week wait time for booking new appointments.

The New Clinics will each offer a range of treatments including ketamine-assisted psychotherapy, SpravatoTM, Cognitive Behavioral Therapy (CBT) and Transcranial Magnetic Stimulation (TMS). The Draper, Murray, and Salt Lake City locations will also offer opportunities for patients to participate in clinical trials for psychedelic medicine that are led by Cedar Clinical Research, Novamind’s clinical research arm. The Park City location will uniquely serve as both a clinic and a retreat center offering therapeutic psychedelic experiences, leveraging its community’s reputation as a world-class destination.

“We are doubling the size of our clinic network six months ahead of schedule, with the added capacity enabling us to scale to 65,000 client visits in 2021,” said Yaron Conforti, CEO and Director of Novamind. “Expect continued and aggressive growth as we expand Novamind’s clinic network and clinical research infrastructure ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”

Novamind is making additional strategic investments in the infrastructure required to support the rapid growth in client volumes at its clinics. A new, dedicated call center is under construction and will enhance Novamind’s network of eight clinics by improving communications with clients and referring physicians, as well as facilitating the significant increase in processing of insurance reimbursements. Additional details for each of the New Clinics and the call center will be announced in subsequent press releases.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, April 24th, 2021

A weekly summary of Novamind news and media

FEATURES April 23, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafy interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FEATURES April 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

OPINION April 21, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

View all media

Novamind Collaborates with Center for Change

April 21, 2021

Novamind Presented at the Planet MicroCap Virtual Event on April 22, 2021

April 19, 2021

Novamind Increases Strategic Investment in Bionomics

April 13, 2021

View all press releases

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

More Americans died from drug overdoses in 2020 than ever before. As psychedelic-assisted treatment options approach mainstream medicine, Time looks at ibogaine as a way to treat addiction like few treatments can.

Psychedelic Drug Worked As Well as Common Antidepressant, Small Trial Finds

Psilocybin works. Researchers in London released findings from a phase 2 trial indicating that a couple of doses of psilocybin may treat depression as well as one of the most commonly prescribed antidepressants. More research is required but leaders of the study were surprised with the outcome.

         Follow @novamind_inc on Instagram

Novamind $NM.ca $NVMDF Collaborates with Center for Change $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Wednesday, April 21st, 2021

Novamind working with Center for Change to treat patients, conduct research

  • Collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders
  • Shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP)
  • There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition

TORONTO, ON / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP). Novamind collaborated on the study with Center for Change, a specialty psychiatric hospital and leading treatment facility for eating disorders.

In a webinar held by Center for Change on April 8th, 2021, Dr. Reid Robison, Novamind’s Chief Medical Officer, discussed early findings from the two studies for eating disorders. The collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders. There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition.

“Novamind is dedicated to researching, developing and delivering new therapeutic protocols to answer unmet needs in mental healthcare,” said Dr. Robison, who also serves as Medical Director for Center for Change. “Our treatment protocols are designed to improve patient outcomes, and we’re proud that renowned facilities like Center for Change recognize that we can provide new options for individuals struggling with eating disorders.”

Novamind offers its clients access to several KAP protocols through Cedar Psychiatry, its wholly owned network of psychiatry clinics. Specialized KAP protocols currently available at Cedar Psychiatry include Emotion-Focused Ketamine-Assisted Psychotherapy and Group Ketamine-Assisted Psychotherapy. Cedar Psychiatry has administered over 7,000 ketamine treatments since 2016 and is undergoing an expansion of its clinic network in the United States.

“Novamind’s psychedelic protocols are informed by the expertise gained from our operating clinics, as well as collaborating with leading medical institutions. We’re pleased to work with Center for Change to advance innovation in mental healthcare,” said Yaron Conforti, CEO and Director of Novamind.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About Center for Change

Center for Change was founded on October 28th, 1994, by a team of psychologists and a physician with a long history together. From those first days, Center for Change began to design the current facility and develop its core treatment programs. A handpicked team of experts forms the backbone of what we do, and they are committed to helping each person get back their life and restore a sense of freedom that may have been absent for far too long.

The Center is licensed with the State of Utah as a Specialty Psychiatric Hospital, and in April 1998, Center for Change received accreditation from The Joint Commission. This accreditation is limited to top organizations delivering high levels of patient service, reducing patient risk and creating an environment for continuous improvement. The Joint Commission has recognized Center for Change for its high standards of patient care and commitment to ongoing education.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Center for Change
Tamara Bingham Noyes, Director of Business Development
Telephone: +1 (888) 224 8250 ext. 267
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Novamind $NM.ca $NVMDF Announces Participation at the Planet MicroCap Showcase on April 20 – 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 2:06 PM on Tuesday, April 20th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

TORONTO, ON / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies you want to know more about; read and watch content from your favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend – all here on SNN.Network.

Contact Information:

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Novamind $NM.ca $NVMDF to Present at the Planet MicroCap Virtual Event on April 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 12:18 PM on Monday, April 19th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.
  • Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors.
  • The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

TORONTO, ON / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

SOURCE: Novamind Inc.

Novamind $NM.ca $NVMDF Increases Strategic Investment in Bionomics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:37 AM on Tuesday, April 13th, 2021
  • Announced that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • Investment supports phase IIb clinical trial examining novel PTSD treatment

TORONTO, ON / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

Novamind purchased an additional 951,133 common shares at AU$0.145 per share for a total investment of AU$137,914 (approximately CAN$132,000) in Bionomics’ recently completed rights offering (the “Rights Offering”). In addition to Novamind’s initial AU$827,486 investment (approximately CAN$810,000) announced on February 11th, 2021, Novamind has invested in Bionomics a total of AU$965,400 (approximately CAN$942,000). Bionomics shares closed at AU$0.20 on April 12th, 2021, a 38% return (unrealized) on Novamind’s total investment.

Proceeds from the Rights Offering will support the initiation of Bionomics’ phase IIb clinical trial for BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). Bionomics is evaluating Cedar Clinical Research, a wholly owned subsidiary of Novamind, as a research site for the BNC210 clinical trial that is anticipated to start mid-2021.

“We are pleased to support the development of a new treatment for PTSD and to be evaluated as a clinical research site for the phase IIb clinical trial of BNC210,” said Yaron Conforti, CEO and Director of Novamind. “Our expertise in clinical research for mental health therapeutics is widely recognized in the biopharmaceutical industry, as demonstrated by our collaboration with Bionomics and recent partnership with Merck.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:28 AM on Saturday, April 10th, 2021

A weekly summary of Novamind news and media

MULTIMEDIA April 8, 2021

Yaron Conforti on Psychedelic Medicine Today and 10 Years from Now

Novamind’s CEO talks with PsyFi about the future of healthcare and the spectrum of alternative services available today in our clinics.

MULTIMEDIA April 8, 2021

Dr. Reid Robison on How Psychedelic Healing Works and Who Benefits From It

Novamind’s CMO talks with Mark Novak about the potential long-term effects of using psychedelics in a therapeutic setting.

INDUSTRY NEWS April 7, 2021

Bringing New Hope to a State Struggling with Mental Illness

The Daily Utah Chronicle speaks with Novamind’s CMO, Dr. Reid Robison, on the game-changing effects of psychedelic-assisted therapy.

View all media

Could Group Therapy Get A Boost From Psychedelics?

A new psychedelic group therapy trial is set to take place this fall with six veterans who suffer from post-traumatic stress disorder. It’s another example of how researchers are investigating psychedelic-assisted group therapy to help patients connect more deeply and broaden access to the potential medical benefits of psychedelics.

UW-Madison Pioneers Master’s Program in Psychoactive Drugs

The University of Wisconsin–Madison School of Pharmacy is launching a new master’s program on Psychoactive Pharmaceutical Investigation. As the first graduate level, degree-based training program for the study and applications of psychedelics, it marks a significant step toward a more global understanding of these groundbreaking therapies, and a highly trained workforce to administer them.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:12 AM on Saturday, March 27th, 2021

A weekly summary of Novamind news and media

INDUSTRY NEWS March 25, 2021

Novamind’s Project with Merck Another Example of Its Research Leadership

Up to 80 million people suffer from treatment-resistant depression and we’re proud to work with one of the most recognized pharmaceutical names in the world to study an alternative. 

FEATURES March 23, 2021

Yaron Conforti Discusses Partnership with Merck for New Treatment-Resistant Depression Trial

Novamind’s CEO talks with George Tsiolis from Agoracom about his excitement to advance research for innovative mental health treatments.

View all media

Novamind to Present at Benzinga Biotech Conference

March 22, 2021

View all press releases

The Federal Government is Funding Research Into Using Psychedelics to Treat Mental Illness. So, Do They Work?

The Australian government is investing $15 million in grants to support research into the use of magic mushrooms, ecstasy and ketamine to combat illnesses that 4 million Australians are currently suffering from. These include post-traumatic stress disorder (PTSD), major depressive disorder, addiction disorders and eating disorders.

Can Magic Mushrooms Heal Us?

Oregon is about to become the first state in America to try and build a support infrastructure through which psychedelic mushrooms can be woven into everyday life. This is very different than others we have seen as it is not about legalization, not about medicalization, but specific to therapeutic use in a licensed facility.

Follow @novamind_inc on Instagram

  

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca

AGORACOM Small Cap 60: Novamind $NM.ca $NVMDF CEOs’ Conviction Grows Every Day $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 3:49 PM on Friday, March 26th, 2021

AGORACOM Small Cap 60: What Does The Recent Partnership With Merck Mean To Novamind? $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 4:01 PM on Thursday, March 25th, 2021